| abstract |
The present inventors were successful in the production of an anti-pyregulin antibody that exhibits cross-reactivity of the species between a non-human animal, a canker monkey, and a human animal, of an anti-pyregulin antibody that rarely undergoes chemical breakdown, of an anti-pyregulin antibody that it has a decreased isoelectric point, of an antiepiregulin antibody that has a high temperature of midpoint of thermal denaturation and of an antiepiregulin antibody that has a reduced amount of aggregates, by correctly replacing an amino acid residue in the sequence with a variable region of a Humanized EP27 antibody that can exhibit cytotoxic activity and neutralization activity in an anti-human epiregulin-expressing cancer cell (i.e., the cancer cell that exhibits an anti-human epiregulin) such that it inhibits the proliferation of the cancer cell. |